Skip to main content

Selzentry FDA Approval History

FDA Approved: Yes (First approved August 6, 2007)
Brand name: Selzentry
Generic name: maraviroc
Dosage form: Tablets
Company: ViiV Healthcare
Treatment for: HIV Infection

Selzentry (maraviroc) is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in patients 2 years of age and older.

Development timeline for Selzentry

DateArticle
Nov  4, 2016Approval ViiV Healthcare Announces FDA Approval of Selzentry (maraviroc) for Use in Children and Adolescents Living With HIV
Aug  6, 2007Approval Pfizer's Selzentry (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA
Jun 21, 2007Pfizer Receives Approvable Letter From FDA For Maraviroc
Apr 25, 2007FDA Advisory Committee Recommends Accelerated Approval of Pfizer’s Maraviroc for Treatment-Experienced Patients
Feb 13, 2007Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe

See also

Selzentry (maraviroc) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer